Condition: Relapsed/Refractory Marginal Zone Lymphoma · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
This description comes directly from the study's public registry record.
Alexia Lu · 010-66609745 · CO_HGRAC@innocarepharma.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Auhui, China | Recruiting |
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Tongren Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Guangdong Provincial Hospital of Chinese Medicine | Guangzhou, Guangdong, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Henan Provincial Peoples Hospital | Zhengzhou, Henan, China | Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| Jiangxi Cancer Hospital | Nanchang, Jiangxi, China | Recruiting |
| The Second Hospital of Dalian Medical University | Dalian, Liaoning, China | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06082102